- Company
- Pricing negotiations for Spinraza's reimb begin in KOR
- by Eo, Yun-Ho Jul 11, 2023 05:41am
- The spinal muscular atrophy treatment ‘Spinraza’ has finally entered the last stage of its reimbursement extension in Korea. According to Dailypharm coverage, Biogen is undergoing drug pricing negotiations with the National Health Insurance Service for its SMA treatment Spinraza (nusinersen). Also, another SMA treatment, Roche Korea
- Company
- Yuhan provides Leclaza with 6 million won per month for free
- by Kim, Jin-Gu Jul 11, 2023 05:40am
- Regarding Yuhan's providing free medicines to patients until the first treatment of Leclaza is covered by insurance, Yuhan said, "It is not an act of inducing patients and there is no problem under the Fair Trade Act." On the 10th, Yuhan held a press conference for permission for the first treatment of Leclaza at the Plaza Hotel in Seoul.
- Company
- Will the non-reimbursed Gavreto vanish in Korea?
- by Jung, Sae-Im Jul 10, 2023 05:21am
- The possibility that the new RET-targeted anticancer therapy ‘Gavreto (pralsetinib)’ will vanish without ever being released in Korea has been rising. With Roche giving up sales rights for Gavreto, the prospects of its reimbursement listing in Korea had also gone up in smoke. As Blueprint Medicines, the original developer of Gavreto, does
- Company
- 3 new asthma drugs resumed discussion on reimbursement
- by Eo, Yun-Ho Jul 10, 2023 05:21am
- Three new asthma drugs, which had been uninsured for at least three years, started the insurance benefit listing process, but only one drug made progress. According to related industries, Handokteva's eosinophilic asthma treatment Cinqair passed the HIRA Pharmaceutical Reimbursement Evaluation Committee. However, GSK Korea's Nucala and Ko
- Company
- New AML drug Vyxeos can be prescribed at general hospitals
- by Eo, Yun-Ho Jul 10, 2023 05:21am
- The new drug ‘Vyxeos’ that was introduced to Korea by Handok Pharmaceuticals may now be prescribed at general hospitals in Korea, According to industry sources, Vyxeos (daunorubicin+ cytarabine), a treatment for adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-
- Company
- Daiichi's sales rose & Astellas' sales fell
- by Jung, Sae-Im Jul 10, 2023 05:20am
- Among Japanese pharmaceutical companies that have entered the domestic market, 4 out of 7 subsidiaries with settlements in March expanded their sales. Daiichi Sankyo Korea's sales reached 253.2 billion won, ranking first among Japanese pharmaceutical companies. As a result of analyzing the performance for the 2022 business year (April 1, 2
- Company
- Boryung’s new drug Zepzelca lands in Big 5 hospitals in KOR
- by Eo, Yun-Ho Jul 7, 2023 05:43am
- Zepzelca, a new drug introduced to Korea by Boryung, can now be prescribed in the Big 5 general hospitals in Korea. According to industry sources, the small cell lung cancer treatment Zepzelca (lurbinectedin) has passed the drug committees (DCs) of all the top 5 tertiary hospitals in Korea &8211; Samsung Medical Center, Seoul National U
- Company
- Release of triple-combo diabetes drugs imminent
- by Kim, Jin-Gu Jul 7, 2023 05:43am
- The release of the ‘triple combination therapies' appear to be in sight. However, unlike the 2-drug combos that are already in fierce competition even in the pre-release stage, industry interest in 3-drug combos is currently at best lukewarm. The pharmaceutical industry pointed to the relatively challenging development environment for
- Company
- Baxter and Fresenius Medical benefited the most
- by Nho, Byung Chul Jul 7, 2023 05:43am
- As the Ministry of Health and Welfare's pilot project for home management of peritoneal dialysis patients began in earnest, the sales of Baxter and Fresenius Medical, which supply related products, are also expected to grow exponentially. As of 2022, total domestic hemodialysis patient medical expenses amounted to 2,634 billion won, of which
- Company
- Vabysmo’s real-world data to hold leader Eylea in check
- by Jung, Sae-Im Jul 6, 2023 05:39am
- The competition between the current lead ‘Eylea’ and the new drug ‘Vabysmo’ is fierce in the macular degeneration treatment market. Based on the real-world data that demonstrated Vabysmo’s consistent effect on patients who switched from Eylea, the company built evidence for patients to switch to Vabysmo. To defend the lead, Eylea’s co
